HER2-directed Biosimilar in Breast Cancer: Real World ePRO
Status: RECRUITING
Study type: OBSERVATIONAL
Conditions: HER2-positive Breast Cancer|Biosimilar|Patient Reported Outcome
Sponsor: OnkoZentrum Zürich AG
Collaborators: University of Zurich|Palleos Healthcare GmbH